Status: Ongoing, but not recruiting participants
ClinicalTrials.gov Identifier: NCT02727881
OHR 1601: A Phase III study of Efficacy and Safety of Squalamine Lactate Opthalmic Solution, 0.2% twice daily in subjects with Neovascular AMD.
Condition: Age-Related Macular Degeneration
Study Type: Interventional
Duration: 36 weeks
For additional information on this study, please click hereBack to Clinical Research